ABX:TSX

Barrick Mining Corporation

Data as of 2026-03-10 - not real-time

CA$62.27

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Barrick Mining Corp. (ABX) trades at C$62.27, well below its DCF‑derived fair value of C$92.21, implying roughly a 30% upside potential. The stock sits just above the 20‑day SMA (C$65.26) and the 50‑day SMA (C$65.67), while the 200‑day SMA (C$46.60) remains far lower, indicating a neutral short‑term bias but a long‑term uptrend. Technicals show a modestly bearish MACD (‑0.52 vs signal +0.11) and an RSI of 42, suggesting limited momentum but no oversold condition. Volume is increasing and volatility is high at 61% over the past 30 days, yet beta is low (0.47), cushioning market‑wide swings. Fundamentally, revenue surged 64.5% YoY to C$16.96 bn, with strong operating (52.6%) and profit margins (29.4%). The company generates robust cash flow (C$7.69 bn operating, C$4.05 bn free) and holds more cash than debt, supporting its 3.72% dividend yield and a modest 18% payout ratio. Recent leadership appointments and the resolution of the Mali dispute enhance governance and geopolitical stability. Analyst consensus (11 analysts) rates the stock as a “buy” with a target median of C$80.21, reinforcing the valuation case. Overall, the blend of undervaluation, solid growth, and sustainable dividends makes ABX attractive across horizons.

Trading Recommendations

Short Term

< 1 year
buy
Conviction: 7/10

Key Factors

  • Price below DCF fair value with ~30% upside
  • Increasing volume and strong cash position
  • Technical support near C$58.48

Medium Term

1–3 years
buy
Conviction: 8/10

Key Factors

  • Sustained revenue growth (64.5%) and high margins
  • Stable dividend yield (3.72%) with low payout
  • Analyst consensus buy and target median C$80.21

Long Term

> 3 years
buy
Conviction: 9/10

Key Factors

  • Long‑term uptrend indicated by 200‑day SMA
  • Strong balance sheet (cash > debt) and low beta
  • Strategic leadership hires and resolved geopolitical disputes

Key Metrics & Analysis

Financial Health

Revenue Growth64.50%
Profit Margin29.45%
P/E Ratio15.4
ROE20.68%
ROA9.97%
Debt/Equity14.51
P/B Ratio2.9
Op. Cash FlowCA$7.7B
Free Cash FlowCA$4.1B

Technical Analysis

TrendNeutral
RSI42.2
SupportCA$58.48
ResistanceCA$70.05
MA 20CA$65.26
MA 50CA$65.67
MA 200CA$46.60
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair ValueCA$92.21
Target PriceCA$80.70
Upside/Downside29.59%
GradeUndervalued
TypeBlend
Dividend Yield3.72%

Risk Assessment

Beta0.47
Volatility61.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.